At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Dr. Hyma Polimera, a Hematology/Oncology Fellow at Penn State Cancer Institute, presented her research regarding COVID-19 vaccine behaviors and outcomes among patients with genitourinary cancers. In this follow-up interview, she explains the efficacy of COVI...

At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Dr. Zain Farooq, Hematologist/Oncologist at H. Lee Moffitt Cancer Center, presented a study investigating gender disparities in National Institutes of Health funding for genitourinary oncology research. In this follow-up interview, Dr. Farooq elaborates on the disparities experienced by women in obtaining genitourinary oncology research grants and shares the next steps for future studies addressing this issue.  

At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, presented his research regarding patient perspectives on fatigue management in prostate cancer. In this follow-up interview, he elaborates on the current lack of information geared toward patients experiencing fatigue while receiving novel hormonal agents and his goal of creating guidance to fill this gap.  

At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Vivian Liu, Lead Clinical Research Coordinator at the University of California, San Francisco (UCSF) Osher Center for Integrative Health, presented her study investigating the association between plant-based diets and risk of disease progression in men with prostate cancer. In this follow-up interview, Ms. Liu shares additional insights into the positive health benefits of a plant-based diet for prostate cancer patients and survivors.  

The FDA has approved nadofaragene firadenovec-vncg (Adstiladrin®, Ferring Pharmaceuticals) for treatment of high-risk Bacillus Calmette-Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Nadofaragene firadenovec-vncg is a non-replicating adenoviral vector-based ge...

An educational activity provided by i3 Health has produced knowledge gains and expertise regarding the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In the United States, prostate cancer is the most common tumor type affecting men. The American Cancer Society estimated for 2022 that there will be 268,490 new cases diagnose...

The FDA has approved darolutamide (Nubeqa®, Bayer HealthCare Pharmaceuticals Inc.) in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). "Standard treatment for patients with metastatic, hormone-sensitive prostate cancer includes the addition of either docetaxel or an androgen-receptor pathway i...

An educational live and enduring activity provided by i3 Health has demonstrated knowledge gains and learning outcomes for nurses treating patients with castration-resistant prostate cancer (CRPC). Prostate cancer is the most common tumor type in men, affecting one in eight men in the United States. The estimate for 2022 is expecting 268,490 new ca...